Drug Profile
Salmeterol injection - Evofem Biosciences
Alternative Names: LIPO-202; Salmeterol xinafoate - Evofem BiosciencesLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Lithera
- Developer Evofem Biosciences
- Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules
- Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Subcutaneous fat disorders
Most Recent Events
- 17 Jan 2018 Evofem Biosciences merged with Neothetics to form Evofem Biosciences
- 08 Sep 2017 Salmeterol injection is still in phase III development for Subcutaneous fat disorders in USA (Neothetics pipeline, September 2017)
- 02 Jun 2017 Neothetics completes the LIPO-202-CL-31 phase II trial for Subcutaneous fat disorders in USA (SC) (NCT03005717)